Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS

AIDS

Volumn 26, Issue 16, 2012, Pages 2111-2112

  Brunel, Anne Sophie ^a   Reynes, Jacques ^a,b   Tuaillon, Edouard ^a,c   Rubbo, Pierre Alain ^a,c   Lortholary, Olivier ^d,e   Montes, Brigitte ^a   Le Moing, Vincent ^a,b   Makinson, Alain ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c UMR 1058 University of Montpellier   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; FLUCONAZOLE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; THALIDOMIDE; IMMUNOSUPPRESSIVE AGENT; STEROID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CRYPTOCOCCAL MENINGITIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; AIDS RELATED COMPLEX; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE AGENTS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; RECURRENCE; STEROIDS; THALIDOMIDE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84867745945     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328358daea     Document Type: Article

References (13)

1. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390.
2. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010; 50:291-322.
3. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10: 791-802.
4. Elliott JH, Vohith K, Saramony S, Savuth C, Dara C, Sarim C, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009; 200:1736-1745.
5. Sitapati AM, Kao CL, Cachay ER, Masoumi H, Wallis RS, Mathews WC. TreatmentofHIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis 2010; 50:e7-e10.
6. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008; 47:e83-e85.
7. Teo SK, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, Thomas SD. Thalidomide in the treatment of leprosy. Microbes Infect 2002; 4:1193-1202.
8. Peterson PK, Hu S, Sheng WS, Kravitz FH, Molitor TW, Chatterjee D, Chao CC. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide-and lipoarabi-nomannan-stimulated human microglial cells. J Infect Dis 1995; 172:1137-1140.
9. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated crypto-coccosis in France. AIDS 2005; 19:1043-1049.
10. van Toorn R, Rabie H, Dramowski A, Schoeman JF. Neurological manifestations of TB-IRIS: a report of 4 children. Eur J Paediatr Neurol 2012; May 30 [Epub ahead of print].
11. Schoeman JF, Springer P, van Rensburg AJ, Swanevelder S, Hanekom WA, Haslett PA, Kaplan G. Adjunctive thalido-mide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004; 19:250-257.
12. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1487-1493.
13. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:2593-2602.